Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL.
[en] Advances in imaging techniques have allowed more precise staging and better evaluation of the effect of new treatment modalities. The limitations of conventional morphologic imaging techniques are well known. Positron emission tomography (PET) using fluorine-18-labeled fluorodeoxyglucose is now routinely used for initial staging and re-evaluation during or after treatment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma (NHL), but not in low-grade NHL. In the first part of this review, the relationship between glucose metabolism as measured by PET, pathological findings including histological grade and proliferative activity, and prognosis are analyzed. In the second part, the potential role of PET in the staging and follow-up of low-grade NHL is discussed. Published data indicate that PET may contribute to the management of low-grade follicular NHL.
Disciplines :
Hematology
Author, co-author :
Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL.
Publication date :
2002
Journal title :
Clinical Lymphoma
ISSN :
1526-9655
Publisher :
Cancer Information Group, Dallas, United States - Texas
Horn N.L., Ray G.R., Kriss J.P. (1976) Gallium-67 citrate scanning in Hodgkin's disease and non-Hodgkin's lymphoma. Cancer 37:250-257.
Brown M.L., O'Donnell J.B., Thrall J.H. (1978) Gallium-67 scintigraphy in untreated and treated non-hodgkin lymphomas. J. Nucl. Med 19:875-879.
Israel O., Front D., Lam M. (1988) Gallium 67 imaging in monitoring lymphoma response to treatment. Cancer 61:2439-2443.
Front D., Israel O. (1995) The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin. Nucl. Med 25:60-71.
Delcambre C., Reman O., Henry-Amar M. (2000) Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy. Eur. J. Nucl. Med 27:176-184.
Newman J.S., Francis I.R., Kaminski M.S. (1994) Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: Correlation with CT. Radiology 190:111-116.
Moog F., Bangerter M., Diederichs C.G. (1997) Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 203:795-800.
Hoh C.K., Glaspy J., Rosen P. (1997) Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J. Nucl. Med 38:343-348.
Jerusalem G., Warland V., Najjar F. (1999) Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl. Med. Commun 20:13-20.
Bangerter M., Moog F., Buchmann I. (1998) Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann. Oncol 9:1117-1122.
Wiedmann E., Baican B., Hertel A. (1999) Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk. Lymphoma 34:545-551.
Partridge S., Timothy A., O'Doherty M.J. (2000) 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution. Ann. Oncol 11:1273-1279.
Jerusalem G., Beguin Y., Fassotte M.F. (2001) Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 86:266-273.
de Wit M., Bumann D., Beyer W. (1997) Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann. Oncol 8(SUPPL. 1):57-60.
Cremerius U., Fabry U., Neuerburg J. (1998) Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl. Med. Commun 19:1055-1063.
Jerusalem G., Beguin Y., Fassotte M.F. (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed imaging. Blood 94:429-433.
Zinzani P.L., Magagnoli M., Chierichetti F. (1999) The role of positron emission tomography (PET) in the management of lymphoma patients. Ann. Oncol 10:1181-1184.
Mikhaeel N.G., Timothy A.R., Hain S.F. (2000) 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann. Oncol 11(SUPPL. 1):147-150.
Spaepen K., Stroobants S., Dupont P. (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J. Clin. Oncol 19:414-419.
Romer W., Hanauske A.R., Ziegler S. (1998) Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 91:4464-4471.
Jerusalem G., Beguin Y., Fassotte M.F. (2000) Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 85:613-618.
Jerusalem G., Beguin Y., Fassotte M.F. (2000) Early detection of relapse by whole-body positron emission tomography (PET) using 18F-fluorodeoxyglucose (18F-FDG) in the follow-up of patients with Hodgkin's disease (HD). Proc. Am. Soc. Clin. Oncol , (Abstract #30); 19.
Warburg O. (1956) On the origin of cancer cells. Science 123:309-314.
Weinhouse S. (1972) Glycolysis, respiration, and anomalous gene expression in experimental hepatomas: G.H.A. Clowes memorial lecture. Cancer Res 32:2007-2016.
Weber G. (1977) Enzymology of cancer cells (first of two parts). N. Engl. J. Med 296:486-492.
Alavi J.B., Alavi A., Chawluk J. (1988) Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 62:1074-1078.
Yonekura Y., Benua R.S., Brill A.B. (1982) Increased accumulation of 2-deoxy-2-[18F]Fluoro-D-glucose in liver metastases from colon carcinoma. J. Nucl. Med 23:1133-1137.
Kern K.A., Brunetti A., Norton J.A. (1988) Metabolic imaging of human extremity musculoskeletal tumors by PET. J. Nucl. Med 29:181-186.
Adler L.P., Crowe J.P., al-Kaisi N.K. (1993) Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 187:743-750.
Leskinen-Kallio S., Ruotsalainen U., Nagren K. (1991) Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study. J. Nucl. Med 32:1211-1218.
Rodriguez M., Rehn S., Ahlstrom H. (1995) Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J. Nucl. Med 36:1790-1796.
Rehn S., Sperber G.O., Nyman R. (1993) Quantification of inhomogeneities in malignancy grading of non-Hodgkin lymphoma with MR imaging. Acta Radiol 34:3-9.
Patlak C.S., Blasberg R.G., Fenstermacher J.D. (1983) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab 3:1-7.
Lapela M., Leskinen S., Minn H.R. (1995) Increased glucose metabolism in untreated non-Hodgkin's lymphoma: A study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 86:3522-3527.
Schrape S., Jones D.B., Wright D.H. (1987) A comparison of three methods for the determination of the growth fraction in non-Hodgkin's lymphoma. Br. J. Cancer 55:283-286.
Hall P.A., Richards M.A., Gregory W.M. (1988) The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J. Pathol 154:223-235.
Okada J., Yoshikawa K., Itami M. (1992) Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity. J. Nucl. Med 33:325-329.
Gjedde A. (1981) High- and low-affinity transport of D-glucose from blood to brain. J. Neurochem 36:1463-1471.
Okada J., Yoshikawa K., Imazeki K. (1991) The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis. J. Nucl. Med 32:686-691.
Isselbacher K.J. (1972) Increased uptake of amino acids and 2-deoxy-D-glucose by virus-transformed cells in culture. Proc. Natl. Acad. Sci. U S A 69:585-589.
Nuutinen J., Leskinen S., Lindholm P. (1998) Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas. Eur. J. Nucl. Med 25:729-735.
Stumpe K.D., Urbinelli M., Steinert H.C. (1998) Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography. Eur. J. Nucl. Med 25:721-728.
Hoffmann M., Kletter K., Diemling M. (1999) Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann. Oncol 10:1185-1189.
Jerusalem G., Beguin Y., Najjar F. (2001) Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann. Oncol 12:825-830.
